Connect with us

Politics

Tulsi Gabbard Talks CBD For Military Members, Biden’s Legalization Opposition And Congressional Retirement

Published

on

Over her eight years in Congress, Rep. Tulsi Gabbard (D-HI) quickly established herself as a leading advocate for marijuana and hemp reform by introducing numerous pieces of cannabis legislation and actively working to build bipartisan support around the issue.

And while the congresswoman will be retiring after this session, she’s made clear she plans to keep pushing legislative reform until her last day on Capitol Hill—and beyond. Last month, for example, she filed an amendment to allow military service members to use hemp-derived CBD at a time when multiple branches are expanding their ban. The House approved the measure, and now it remains to be seen if it can survive bicameral negotiations with the Senate.

A military veteran herself, Gabbard says the non-intoxicating cannabinoid represents a promising alternative treatment for those on the front lines and argued, contrary to military leaders, that it can actually improve readiness. And while it remains to be seen whether her measure will make it to the president’s desk, she says moving leadership in that direction will be a priority in the weeks ahead.

Marijuana Moment caught up with the congresswoman, who made legalization a centerpiece of her 2020 Democratic presidential campaign, in a phone interview. She discussed her amendment, the evolving politics of cannabis reform, former presidential primary opponent Joe Biden’s opposition to marijuana legalization and more.

Marijuana Moment’s Patreon supporters can listen to the audio recording of our conversation with Gabbard. In addition to the topics covered in this publicly available writeup of the interview, the congresswoman also talks about whether she has plans to join the cannabis industry after leaving Congress and reacts to the Democratic National Committee’s refusal to endorse legalization.

The exclusive audio clip is available for supporters who help make our cannabis journalism possible with monthly pledges of $10 or more.

This premium content is available only for Marijuana Moment supporters on Patreon. Please start a monthly pledge to help us continue our cannabis advocacy journalism. (Please contact [email protected] if you are a patron and have trouble logging in.)

This interview has been lightly edited for length and clarity. 

Marijuana Moment: I wanted to start by asking about your CBD amendment. What motivated that, and have you heard from service members about the need for this legislation?

Tulsi Gabbard: I have, and it really came about as a result of the changes that were included in the 2018 Farm Bill that really opened a lot of doors of opportunity for more research and more products to come into the market that can help people with day-to-day ailments that, as a service member, I’m very well aware are common occurrences.

Being able to have other options of alternative forms of treatment other than, ‘Hey, just take another Motrin or prescription drug X, Y or Z’ is something that can actually increase our service members’ health and wellbeing and, ultimately, their readiness to be able to do their job.

MM: It was interesting to see just days after the House approved the measure, the Navy announced it was expanding its CBD ban, prohibiting members from using even products like hemp-infused shampoos and conditioners. What do you make of that?

TG: It seemed really strange and, frankly, almost silly. I don’t know what instigated that change, and I’m not going to make any assumptions. But, you know, it just speaks, to me, a very backward way of viewing these products and the changes that are being made in both state and federal law as it relates to CBD and hemp products.

MM: Do you have any thoughts about the prospects of advancing the amendment through the House-Senate conference committee? Are you talking to leadership about that process?

TG: It’s something we’re working on currently. I think it’s too early to say, but conference can be a place where great things go to die unfortunately so we’re trying to do as much work as we can, both with senators on the Senate Armed Services Committee—those who anticipate being in the conference committee—as well as the leadership to make sure that this and a few other key amendments that we included in the House bill actually stay in the bill.

MM: Looking back at your time in Congress, what would you say about the way its evolved on this issue?

TG: It has been interesting over my eight years in Congress to see how this issue at the very beginning of my first term in office was something that, you know, you could tell the people who were for and against. It was mostly partisan, but also just based on people saying things like, “I don’t want my kids to smoke pot” and therefore voting against any legislation that had anything to do with whether it was decriminalization as a whole or taking it off the [Controlled Substances Act] or even saying, “Hey, for states where it’s legal, we should allow people to use our banking system.”

But it’s changed, I feel, too slowly, but it is changing over the years to where we’ve built support, as we saw even recently in some amendments to the appropriations bill to people who are saying, “Hey look, this is a states’ right issue.” Those who may have been opposed traditionally are recognizing that, in states where this is legal, we should be supporting the state’s decision in that. And frankly, others who, whether through personal experience or through actually doing research, are seeing that there just are so many fear-based myths that have perpetuated opposition, where there’s actually some incredible game-changing research being done both from a medical perspective as well as from an economic opportunity perspective, as we’ve seen in Kentucky obviously.

This is something that we should support more of the exploration of and the introduction into our everyday commerce and lives.

MM: Speaking of Kentucky, Senate Majority Leader Mitch McConnell (R-CA) and other Republicans recently criticized House Speaker Nancy Pelosi (D-CA) over her defense of including cannabis banking language in your chamber’s latest COVID-19 relief bill. They argue it’s not germane. Do you feel its a relevant provision for this legislation?

TG: I think it’s relevant because, from the data I’ve seen, the numbers of people who’ve been going to their local dispensary has dramatically increased in the midst of this pandemic. By continuing to disallow anyone associated with these industries that states have deemed legal is further perpetuating serious problems and uncertainty during time when, frankly, we need as much certainty as we can get.

Marijuana Moment asked Gabbard about whether she has plans to work in the marijuana industry following her retirement from Congress early next year, as other lawmakers have done. She also reacted to the Democratic National Committee’s rejection of a cannabis legalization platform plank. 

The congresswoman’s answers to those questions, and the full audio of our interview, are available exclusively for Marijuana Moment supporters pledging at least $10/month on Patreon.

This premium content is available only for Marijuana Moment supporters on Patreon. Please start a monthly pledge to help us continue our cannabis advocacy journalism. (Please contact [email protected] if you are a patron and have trouble logging in.)

MM: Presumptive Democratic presidential nominee Joe Biden remains opposed to legalizing marijuana. What message would you send to the former vice president about the importance of embracing the policy change?

TG: I would speak from personal experience—just the more information that I’ve learned, the more research that I have done, it shows how, number one, outdated our laws are as it relates to cannabis in particular and how much opportunity there is, again from a medical perspective as well as from an economic perspective, especially related to hemp, which is you know why I introduced the Hemp For Victory Act. There’s tremendous opportunity available. I would urge him to examine this information with the hopes that, with information, he would be willing to reconsider his position.

MM: A staffer to a committee chair told us recently that there are plans in the work to put House Judiciary Chairman Jerrold Nadler’s (D-NY) marijuana legalization bill on the floor for a vote in September. Have you heard anything about that?

TG: I have not, about the scheduling of it. I know that the chairman has been very committed to moving this forward and that we knew from the beginning that of any cannabis-related legislation, it would likely be something like this that would have the greatest chance of actually getting a vote on the House floor. So I’m hopeful.

MM: Are you optimistic about the prospect of legalization advancing in your state of Hawaii in the near future?

TG: I don’t know is the honest answer to that. This just shows that cannabis legislation is not limited to party lines because we’ve got a very strong Democratic legislature here in the state, obviously a Democratic governor, but there have been very strange responses, in my opinion, to some of the cannabis-related legislation. So it remains to be seen.

Just to add to that, one example that continues to perplex me is the data very clearly shown how, in states where there is some form of legal cannabis use in place, medicinal or otherwise, a direct correlation with the reduction of opioid addiction and opioid-related deaths. That’s an indisputable fact. However, even with bipartisan support, bicameral support, in the passage of legislation that would make opioid addiction eligible for medicinal marijuana use in our state, that bill was vetoed by our Democratic governor, claiming a lack of evidence and information and stating that, if proponents want to push this, they should go through the Department of Health bureaucracy to do so.

Things like that, frankly, scientifically it makes no sense. And in the way of people in a state like ours where just under, I think last time I checked, just under like 500,000 active opioid prescriptions in a state with a population of about 1.3 million people. There’s clearly an issue here, and by providing this, you give people an alternative form of treatment.

MM: Looking back at your eight years in Congress, what are you most proud of in terms of advancing cannabis reform?

TG: You know, I’ve introduced a number of pieces of legislation, amendments, provisions in larger bills throughout my time in Congress, and I appreciate having played a role in helping to build bipartisan support for some of the changes that we’ve actually seen take place.

It may sound like, “Well, that’s not much,” but when you work in a place where too many members of Congress on both sides of the aisle are unwilling to have real dialogue and conversations with one another purely because of prejudging them based on their partisan affiliation, this is exactly the only way how we’ll actually make change around these and other important issues that impact all Americans, not just those of one party or another.

MM: Is there anything else you want to add?

What’s going to be interesting is whether the Pentagon, obviously, whether officially or unofficially weighs in on [the NDAA CBD and hemp amendment]. That is going to be an issue of contention with that. We’ll see.

Become a Marijuana Moment supporter on Patreon with a monthly pledge of $10 or more to hear our conversation with Gabbard and to support our ongoing cannabis journalism that helps to keep you informed about key developments.

D.C. Would Vote To Decriminalize Psychedelics, Poll Shows

Photo element courtesy of Lorie Shaull.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Politics

Marijuana Bill Up For House Vote Could ‘Reverse’ Federal-State Policy Gap, Congressional Research Service Says

Published

on

A bill to federally legalize marijuana that is scheduled for a House vote next week could “reverse” the current cannabis policy gap that exists between states and the federal government, a new Congressional Research Service (CRS) report says.

In an analysis of the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act that was published on Wednesday, CRS described the various complications resulting from ongoing federal prohibition as more states opt to legalize cannabis for medical or recreational purposes. The research agency said the legislation could inadvertently create a new schism where federal policy would be more progressive than those of certain states.

That’s because the bill does not require states to stop criminalizing cannabis, and so jurisdictions with prohibition still on the books could continue to punish people over marijuana even as such activity is legalized at the federal level.

“If the MORE Act became law, it could create a new divide between federal and state law—essentially the reverse of the current marijuana policy gap, since federal marijuana law would become less strict than some state laws,” CRS wrote. “The MORE Act could also highlight the inconsistency between marijuana laws in different U.S. jurisdictions by repealing the uniform federal prohibition and leaving in place a patchwork of varying state laws.”

The MORE Act, whose lead sponsor is Judiciary Committee Chairman Jerrold Nadler (D-NY), would federally deschedule cannabis, expunge the records of those with prior marijuana convictions and impose a federal five percent tax on sales, revenue from which would be reinvested in communities most impacted by the drug war.

The legislation would also create a pathway for resentencing for those incarcerated for marijuana offenses, as well as protect immigrants from being denied citizenship over cannabis and prevent federal agencies from denying public benefits or security clearances due to its use.

“Congress may be content to allow states to experiment with varying approaches to marijuana regulation,” CRS said. “In the alternative, Congress might prefer a more uniform approach, whether that approach is to criminalize or decriminalize marijuana, or something in between. However, while Congress can pass legislation creating a uniform federal policy, there are limits to its ability to affect state law.”

The agency said that while lawmakers lack the “constitutional authority to alter state criminal law,” they could “preempt state law through Commerce Clause legislation” or “encourage states to change their laws through the use of the spending power.”

To that end, while the MORE Act does not create a federal regulatory structure for cannabis or force states to change their own laws, it does include provisions that incentivize the adoption certain local reform policies. For example, it offers federal funding for “eligible states” that take steps to expunge prior cannabis convictions and stop penalizing people on parole for marijuana-related offenses.

“Congress could also invoke its spending power to encourage states to regulate marijuana more stringently, and has previously used the spending power to shape drug policy in targeted ways,” CRS said.

These and other considerations will likely be the subject of significant debate when the House takes up the MORE Act next week.

House Majority Leader Steny Hoyer (D-MD) announced on Friday that the bill will be taken on the floor as soon as Wednesday.

He had previously said this summer that the chamber would vote on the legislation in September, but that plan was postponed following pushback from certain centrist Democrats who worried about the optics of advancing cannabis reform before passing another coronavirus relief package.

The bill cleared Nadler’s more than a year ago and has been awaiting floor action since.

Even if the far-reaching reform does pass in the Democratic-controlled chamber, as it’s expected to with some bipartisan support, it remains unlikely that the Senate will follow suit, at least during this Congress. Majority Leader Mitch McConnell (R-KY) is a champion of the hemp industry but staunchly opposes further marijuana reform.

Even so, a symbolic vote for legalization could send a strong signal to the incoming Biden administration. Vice President-elect Kamala Harris (D-CA) is the lead Senate sponsor of the MORE Act, but she’s indicated she will not necessarily proactively push the former vice president to evolve further on cannabis reform.

Given Biden’s former approach to championing punitive anti-drug legislation as a senator and his ongoing obstinance on marijuana legalization at a time when polls show that a clear majority of Americans favor the policy change, there remains some skepticism about his willingness to make good on his campaign promises to achieve more modest reforms he has endorsed, such as decriminalizing possession and expunging records.

A transition document the incoming Biden-Harris administration released this month left out mention of those cannabis pledges.

That said, the president-elect has conceded that his work on punitive anti-drug legislation during his time in Congress was a “mistake.”

For what it’s worth, Rep. Earl Blumenauer (D-OR) told Marijuana Moment in August that “the Biden administration and a Biden Department of Justice would be a constructive player” in advancing legalization.

CRS, in its new report, also discussed broader drug policy reform efforts taking place at the state level and locally, such as Oregon’s recent vote to decriminalize possession of all currently illicit drugs. The agency noted moves to decriminalize psychedelics specifically in Washington, D.C., too.

These “current trends suggest that there may be a broader movement toward decriminalizing controlled substances,” CRS said. “Comprehensively addressing such changes is outside the scope of the MORE Act, but Congress may wish to monitor developments in this area when considering future legislation.”

Mexico’s President Says Legal Marijuana Is About Freedom, As Legislation Advances In Congress

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Federal Marijuana Legalization Bill Will Get A Congressional Vote Next Week, Leader Announces

Published

on

A bill to federally legalize marijuana will receive a full floor vote in the U.S. House of Representatives next week, a top Democratic leader in the chamber announced on Friday.

House Majority Leader Steny Hoyer (D-MD) said the chamber will take up the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act some time between Wednesday and Friday. The floor schedule announcement comes weeks after the leader first confirmed that the House would advance the proposal before the year’s end.

Early in the week, the bill is first expected to go before the House Rules Committee, which prepares legislation for floor action and decides which amendments can be made in order for consideration by the full body.

Hoyer previously said that the chamber would vote on the legislation in September, but that plan was postponed following pushback from certain centrist Democrats who worried about the optics of advancing cannabis reform before passing another coronavirus relief package. Several moderates ended up losing their reelection races this month on the same dat that voters in several red states approved legalization measures, however, raising questions about their strategic thinking on the politics of marijuana.

“I’ve been working on this issue longer than any politician in America and can confidently say that the MORE Act is the most comprehensive federal cannabis reform legislation in U.S. history,” Rep. Earl Blumenauer (D-OR) said in a press release. “Our vote to pass it next week will come after people in five very different states reaffirmed the strong bipartisan support to reform the failed cannabis prohibition. National support for federal cannabis legalization is at an all-time high and almost 99 percent of Americans will soon live in states with some form of legal cannabis.”

“Congress must capitalize on this momentum and do our part to end the failed policy of prohibition that has resulted in a long and shameful period of selective enforcement against communities of color,” he said.

The House approving the bill during the presidential transition could also raise the pressure on President-elect Joe Biden to embrace legalization—a policy he’s declined to adopt despite supermajority support among Democratic voters.

As currently written, the MORE Act, whose lead sponsor is Judiciary Committee Chairman Jerrold Nadler (D-NY), would federally deschedule cannabis, expunge the records of those with prior marijuana convictions and impose a federal five percent tax on sales, revenue from which would be reinvested in communities most impacted by the drug war.

The legislation would also create a pathway for resentencing for those incarcerated for marijuana offenses, as well as protect immigrants from being denied citizenship over cannabis and prevent federal agencies from denying public benefits or security clearances due to its use.

All of those provisions are subject to change through amendments over the coming week.

“This floor vote represents the first congressional roll call ever on the question of ending federal marijuana criminalization,” NORML Political Director Justin Strekal told Marijuana Moment. “By advancing the MORE Act, the House of Representatives sends an unmistakable signal that America is ready to close the book marijuana prohibition and end the senseless oppression and fear that this failed policy wreaks on otherwise law-abiding citizens.”

“Americans are ready to responsibly legalize and regulate marijuana, and this vote shows some lawmakers are finally listening,” he said.

The bill cleared Nadler’s more than a year ago and has been awaiting floor action since.

Even if the far-reaching reform does pass in the Democratic-controlled chamber, as it’s expected to with some bipartisan support, it remains unlikely that the Senate will follow suit, at least during this Congress. Majority Leader Mitch McConnell (R-KY) is a champion of the hemp industry but staunchly opposes further marijuana reform.

Even so, a symbolic vote for legalization could send a strong signal to the incoming Biden administration. Vice President-elect Kamala Harris (D-CA) is the lead Senate sponsor of the MORE Act, but she’s indicated she will not necessarily proactively push the former vice president to evolve further on cannabis reform.

Given Biden’s former approach to championing punitive anti-drug legislation as a senator and his ongoing obstinance on marijuana legalization at a time when polls show that a clear majority of Americans favor the policy change, there remains some skepticism about his willingness to make good on his campaign promises to achieve more modest reforms he has endorsed, such as decriminalizing possession and expunging records.

A transition document the incoming Biden-Harris administration released this month left out mention of those cannabis pledges.

That said, the president-elect has conceded that his work on punitive anti-drug legislation during his time in Congress was a “mistake.”

For what it’s worth, Rep. Earl Blumenauer (D-OR) told Marijuana Moment in August that “the Biden administration and a Biden Department of Justice would be a constructive player” in advancing legalization.

Marijuana Legalization Opponents Ask Courts To Overturn Voters’ Will In Several States

Image element courtesy of Tim Evanson.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Two-Track Effort To Allow Psychedelic Mushrooms In Washington State Launches Amid Broader Drug Decrim Push

Published

on

Drug reform advocates won big in Oregon this year, with separate ballot measures to decriminalize possession of all drugs and legalize psychedelic mushrooms for therapeutic use passing on Election Day. Now organizers are setting their sights on similar reforms next door in Washington State with two newly announced efforts.

One seeks to utilize existing administrative mechanisms to expand access to psilocybin mushrooms for therapeutic use by patients in end-of-life care. The other, a proposed ballot initiative on track for 2022, would put Washington on par with Oregon, decriminalizing small-scale possession of all drugs and legalizing mushrooms for broader therapeutic use.

These efforts come after advocates already announced a separate plan to lobby lawmakers to pass a bill decriminalizing all drugs in 2021.

A healthcare professional is behind the first new psilocybin push via the administrative route. Dr. Sunil Aggarwal, a Seattle physician who specializes in end-of-life care, is hoping to win permission from state and federal regulators to cultivate psilocybin mushrooms and use them to treat patients.

“We know that it’s a naturally occurring substance that we can cultivate safely, we know how to dose it, and there’s really good reason to believe it can help,” Aggarwal said of psilocybin, the main active ingredient in entheogenic mushrooms.

Aggarwal and his clinic, the Advanced Integrative Medical Science Institute, hope to secure legal access to psilocybin for end-of-life patients under state and federal laws that allow patients with terminal diseases to try investigational medications that haven’t been generally approved.

In 2018, President Donald Trump signed the federal “Right to Try Act,” which would give certain patients access to drugs that have not yet been cleared by the U.S. Food and Drug Administration for broad use. Psilocybin, along with marijuana and MDMA, appears to fit the criteria for the law, including having completed a phase 1 clinical trial and being under active development. Washington State adopted a similar law in 2017.

In September, Aggarwal applied to the Washington State Department of Health’s Pharmacy Quality Assurance Commission for a license to grow psilocybin mushrooms with the eventual goal of using them to treat patients in palliative care. The state commission has yet to review the application, Kaiser Health News reported this week.

Aggarwal would also need to obtain approval from the federal government, namely the U.S. Drug Enforcement Administration (DEA). “We’re still working on formulating an application to them,” he told Marijuana Moment in a phone interview, adding that his team is consulting with lawyers for guidance.

As for a timeline on the applications? “I wish I could tell you,” Aggarwal said. “There’s really no way to know. This has never been tried before that we’re aware of.”

Meanwhile, more sweeping statewide reform could come in the form of a 2022 ballot question. A top backer of both of Oregon’s successful drug-reform initiatives recently said Washington is the next state on his list.

David Bronner, CEO of Dr. Bronner’s soap company, has long bankrolled drug reform campaigns. In Oregon last election, he gave $3.4 million to Measure 109, which legalized psilocybin for therapeutic use, and $1 million to Measure 110, which decriminalized all drugs.

Bronner recently told the Daily Beast that he’d like to see Washington voters pass both reforms—medical psilocybin and broader drug decriminalization—in a single initiative on the state’s 2022 ballot.

“It’s moving faster than I would’ve thought,” he said. “I would not have thought we’d be ready for the kind of reforms we’re seeing, and it’s gratifying. I just think we can go further in 2022 and 2024.”

Bronner added that he hopes to team up with other drug-reform funders, such as Mark Zuckerberg and George Soros, to maximize their policy impact. “If we all line up as one grand coalition, we can run twice as many ballot measures in a given cycle,” he told the Daily Beast. “We’re working hard on figuring that out.”

In the meantime, another group of activists in the state are continuing their push for drug decriminalization. Treatment First Washington hopes to see lawmakers take up a proposed decriminalization measure next year that closely resembles Oregon’s Measure 110.

The group originally planned to qualify the Washington measure for the 2020 election, but organizers stopped collecting signatures in the spring due to the COVID-19 pandemic.

As with Oregon’s recently passed decriminalization measure, Treatment First Washington’s proposal would remove criminal penalties for drug possession, expand treatment for substance misuse and pay for that treatment with tax revenue from the state’s legal cannabis industry.

Aggarwal, the Seattle doctor applying to cultivate mushrooms, said that any of the reform efforts would likely help expand access for his patients.

“This effort would definitely be a lot easier if we had decriminalization,” he said, explaining that treatment could work similarly to how the clinic currently deals with marijuana.

“We kind of do this with cannabis in our office already,” he said. “People can do cannabis-assisted therapy sessions where they bring their own, and there’s a vaporizer and they can have a session with a decriminalized drug.”

Aggarwal said he filed the application because dying patients can’t wait for broader reform through the legislature or the ballot box.

“We just don’t have time to wait for that for patients who are sick now,” he said. “These are patients that really have exhausted legally available psychedelic-assisted therapy, which is ketamine, and I think there’s still a need for more… They need help now and not in 2022.”

Marijuana Legalization Opponents Ask Courts To Overturn Voters’ Will In Several States

Photo courtesy of Wikimedia/Workman

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!